PHARMACY

Fruth Pharmacy promotes Tim Weber to VP

BY Alaric DeArment

POINT PLEASANT, W.Va. — Fruth Pharmacy has promoted director of pharmacy administration and procurement Tim Weber to VP, the regional retail pharmacy chain said Thursday.

In the new position, Weber will lead the chain’s pharmacy division. He previously held positions at Eckerd Drug Company and Sears Holdings.

"One of our best successes to date is our migration from legacy PDX to a workflow-orientated Enterprise Pharmacy System," Weber said. "This system enables Fruth to optimize the filling process and gives our pharmacy teams more functionality within the daily workflow to better serve our patients. Fruth has been able to advance our clinical services to our patients due to this improvement by integrating medication therapy management into the pharmacy workflow."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan launches cabergoline tablets

BY Alaric DeArment

PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.

Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan completes acquisition of Agila from Strides Arcolab

BY Alaric DeArment

PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila’s U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.

"The acquisition of Agila will create a global injectables leader, expanding and strengthening Mylan’s existing injectables platform and portfolio and providing Mylan entry into exciting new geographic markets," Mylan CEO Heather Bresch said. "We believe we can generate significant growth from this business as we maximize the capabilities of this platform and accelerate the many untapped opportunities we see ahead."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES